Form 4: Edgewise Therapeutics CEO Kevin Koch Reports Stock Transactions
SEC Form 4
Edgewise Therapeutics CEO Kevin Koch reports the acquisition and disposal of company stock, including sales to cover tax obligations related to vested Restricted Stock Units (RSUs).
Summary
- On May 1, 2024, Kevin Koch, the President and CEO of Edgewise Therapeutics, acquired 10,417 shares of common stock through the vesting of Restricted Stock Units (RSUs).
- On May 2, 2024, Koch sold 3,152 shares of common stock at an average price of $18.91 per share, with prices ranging from $18.68 to $19.12.
- The sale was to cover statutory tax withholding obligations related to the RSU vesting and wasn't a discretionary sale.
- Following these transactions, Koch directly owns 14,478 shares of common stock.
- Koch also indirectly owns 259,554 shares through the KTK Family Enterprise, LLC, and 26,410 shares each through the Adrienne R. Koch Heritage Trust, the Matthew K. Koch Heritage Trust, and the Nicole M. Soldow Heritage Trust, for which he serves as co-trustee or manager.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the document primarily reports routine stock transactions related to executive compensation. The sale of shares to cover taxes is a common practice and doesn't necessarily indicate a negative outlook.
Positives
- The acquisition of shares through RSU vesting aligns the CEO's interests with those of the shareholders.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gauge management's sentiment about the company's prospects.
Comparison to Industry Standards
- Insider transactions are a normal part of executive compensation and wealth management.
- Companies like Amgen, Regeneron, and Vertex Pharmaceuticals also have executives who regularly report stock transactions.
- The sale of shares to cover tax obligations is a standard practice.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the small volume of shares sold.
Key Dates
| Date | Description |
|---|---|
| 05/01/2023 | Beginning date of RSU vesting in three equal annual installments. |
| 05/01/2024 | Date of RSU vesting and acquisition of 10,417 shares. |
| 05/02/2024 | Date of sale of 3,152 shares to cover tax obligations. |
| 05/03/2024 | Date of signature of the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.